Becton Dickinson and Co (BDX) CEO Thomas Polen on Q3 2022 Results - Earnings Call Transcript

Becton Dickinson and Co (NYSE:BDX) Q3 2022 Earnings Conference Call August 4, 2022 8:00 AM ET

Company Participants

Francesca DeMartino - SVP & Head, IR

Thomas Polen - President, CEO & Chairman

Christopher DelOrefice - EVP & CFO

Simon Campion - EVP, President, Medical Segment & Interim President, Interventional Segment

David Hickey - Executive VP & President, Life Sciences Segment

Conference Call Participants

Lawrence Biegelsen - Wells Fargo Securities

Vijay Kumar - Evercore ISI

Robert Marcus - JPMorgan Chase & Co.

Frederick Wise - Stifel, Nicolaus & Company

Travis Steed - Bank of America Merrill Lynch

Operator

Hello, and welcome to BD's Earnings Call for the Third Quarter of Fiscal 2022. At the request of BD, today's call is being recorded and will be made available for replay through August 11, 2022 on BD's Investor Relations website on bd.com or by phone at 866-342-8591 for domestic calls and area code +1-203-518-9713 for international calls. The replay bridges are now dedicated, so you no longer need a conference ID to hear the replay. [Operator Instructions]. I will now turn the call over to BD.

Francesca DeMartino

Good morning, and welcome to BD's earnings call. I'm Francesca DeMartino, Senior Vice President and Head of Investor Relations. On behalf of the BD team, thank you for joining us. This call is being made available via audio webcast at bd.com.

Earlier this morning, BD released its results for the third quarter of fiscal 2022. We also posted an earnings presentation that provides additional details on our performance. The press release and presentation can be accessed on the IR website at investors.bd.com.

Leading today's call are Tom Polen, BD's Chairman, Chief Executive Officer and President; and Chris DelOrefice, Executive Vice President and Chief Financial Officer. Tom will provide highlights of our performance and the continued execution of our BD2025 strategy. Chris will then provide a financial review and our increased revenue and EPS guidance for fiscal 2022. Following the prepared remarks, Tom and Chris will be joined for Q&A by our segment presidents, Simon Campion, President of the Medical segment; and Dave Hickey, President of the Life Sciences segment.

Before we get started, I want to remind you that we will be making forward-looking statements. I encourage you to read the disclaimer in our earnings release and the disclosures in our SEC filings, which are both available on the Investor Relations website. Unless otherwise specified, all comparisons will be on a year-over-year basis versus the relevant period. Revenue percentage changes are on an FX-neutral basis unless otherwise noted.